Peptide Schedule
Vasopressin (Vasostrict)9 residuesCYFQNCPRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Vasopressin (Vasostrict) Dosage Calculator
Vasopressin, also known as arginine vasopressin (AVP) or antidiuretic hormone (ADH), is a cyclic nonapeptide (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2) with a disulfide bridge between the two cysteine residues at positions 1 and 6.
0.01mcg · Daily
Summary: Add 0mL BAC water to your 20mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.01mcg dose. This vial will last 0 doses.
Cycle Planner
Vasopressin (Vasostrict) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = 10-20 minutes (IV)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Vasopressin (Vasostrict) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.01 IU | Daily |
| Moderate | 0.03 IU | Daily |
| Aggressive | 0.04 IU | Daily |
Note: Vasopressin (arginine vasopressin, AVP, antidiuretic hormone/ADH) is an endogenous nonapeptide hormone synthesized in the supraoptic and paraventricular nuclei of the hypothalamus and released from the posterior pituitary. It is FDA-approved as Vasostrict for the treatment of vasodilatory shock in adults. Vasopressin is administered exclusively by continuous intravenous infusion in critical care settings; the dosing tiers shown reflect standard ICU infusion rates in units per minute (U/min). The typical starting dose is 0.01-0.04 U/min, titrated to hemodynamic response. It is NOT a peptide for self-administration or wellness use. All vasopressin therapy must occur under direct physician supervision with continuous hemodynamic monitoring. Premixed ready-to-use formulations are available and preferred to reduce medication errors. Vasopressin should be tapered gradually rather than discontinued abruptly to avoid rebound hypotension and transient diabetes insipidus.
About Vasopressin (Vasostrict)
Vasopressin, also known as arginine vasopressin (AVP) or antidiuretic hormone (ADH), is a cyclic nonapeptide (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2) with a disulfide bridge between the two cysteine residues at positions 1 and 6. It is synthesized as a preprohormone in magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei, then transported along axons to the posterior pituitary gland where it is stored in secretory granules and released in response to increased plasma osmolality, hypovolemia, or hypotension. Vasopressin was first isolated and synthesized by Vincent du Vigneaud in 1954, earning him the Nobel Prize in Chemistry in 1955. The synthetic form used clinically is 8-L-arginine vasopressin, identical to the endogenous human hormone. Vasostrict, the branded injectable formulation manufactured by Endo International (now Par Pharmaceutical), received FDA approval in 2014 for the treatment of vasodilatory shock in patients who remain hypotensive despite fluid resuscitation and catecholamines. The hormone exerts its physiological effects through three distinct G protein-coupled receptor subtypes: V1a receptors on vascular smooth muscle mediate vasoconstriction via the Gq/phospholipase C/IP3/calcium pathway; V2 receptors on renal collecting duct principal cells promote water reabsorption via Gs/cAMP-mediated insertion of aquaporin-2 channels into the apical membrane; and V1b (V3) receptors in the anterior pituitary stimulate ACTH secretion. Additional effects include platelet aggregation, hepatic glycogenolysis, and release of von Willebrand factor and Factor VIII from vascular endothelium (via V2 receptors). Clinically, vasopressin is primarily used in three major settings: vasodilatory shock (septic, postcardiotomy, or other distributive shock) as a catecholamine-sparing vasopressor, central diabetes insipidus (as replacement therapy for ADH deficiency), and acute variceal hemorrhage in the GI tract (to reduce splanchnic blood flow). The landmark VASST trial (2008) and VANISH trial (2016) established its role as an adjunctive vasopressor in septic shock. Vasopressin is also included in the Advanced Cardiovascular Life Support (ACLS) algorithm as an alternative to epinephrine in cardiac arrest, though recent guidelines have de-emphasized this indication.